Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
empagliflozin + lobeglitazone
- Development stage
- Unknown
- Lead developer
- Boehringer Ingelheim
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Empagliflozin + lobeglitazone is a fixed-dose combination of two oral antidiabetic agents used for the management of type 2 diabetes mellitus. Empagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that lowers blood glucose by promoting urinary glucose excretion through inhibition of renal SGLT2 transporters in the proximal tubules[1][6]. It also provides cardiovascular and renal benefits, reducing risks associated with heart failure and kidney disease[1][6]. Lobeglitazone is a thiazolidinedione-class insulin sensitizer that acts as an agonist at peroxisome proliferator-activated receptor gamma (PPARγ), improving insulin sensitivity in adipose tissue and lowering blood sugar levels[4][5]. The combination targets complementary mechanisms to enhance glycemic control without significant pharmacokinetic interactions between the two drugs, making them suitable for coadministration in patients with type 2 diabetes[3][5].
- Other names
- empagliflozin + lobeglitazone
02
Targets
SGLT2 (Sodium-glucose cotransporter protein subunit 2)PPARG (Peroxisome proliferator-activated receptor gamma)
Beyond the preview
Go deeper on empagliflozin + lobeglitazone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on empagliflozin + lobeglitazone.